Recovery Blueprint: Mifepristone Access and the Standing Doctrine

The Structural Problem

The Supreme Court's decision in FDA v. Alliance for Hippocratic Medicine preserved access to mifepristone—not by affirming the FDA's regulatory judgment, but by ruling that the plaintiffs lacked standing to challenge it. This procedural off-ramp leaves the underlying mechanism unrepaired: the FDA's premarket approval authority remains exposed to cyclical challenge by motivated plaintiffs seeking favorable forums, and the standing doctrine itself operates without clear guardrails when speculative harms meet ideological objections.

The immediate threat was averted. Mifepristone remains available under the FDA's 2016 and 2021 risk evaluation protocols. But the structural vulnerability persists. A different plaintiff—one with more carefully crafted allegations of injury—could reignite the same dispute. The dissents by Justices Alito and Thomas signal willingness to revisit both the standing question and the merits if presented with a marginally better case. Meanwhile, regulatory agencies confront the reality that decades-old drug approvals, backed by extensive safety data, can be hauled into litigation by parties with no direct regulatory interest.

This is not a problem of abortion politics alone. It is a design flaw in how administrative expertise interacts with judicial review and adversarial standing doctrine. The system allows proxy battles over policy to be waged through the machinery of Article III, and it tolerates forum shopping that turns federal district courts into de facto national regulators.

The Root Cause

The root cause is threefold:

First, the standing doctrine as currently applied operates with insufficient rigor in cases involving regulatory approvals. The threshold for alleging injury is low enough to permit claims grounded in speculative chains of causation (e.g., a physician might encounter complications from a drug someone else prescribed). This invites litigation as a form of policy advocacy.

Second, there is no statutory or procedural mechanism that consolidates multi-district challenges to FDA drug approvals in a single forum. The current system permits plaintiffs to select jurisdictions with favorable judicial records, leading to conflicting injunctions and nationwide chaos over products approved through uniform federal processes.

Third, the Administrative Procedure Act provides a broad right to challenge "agency action," but it does not distinguish between recent regulatory decisions and long-settled approvals with decades of safety data. This temporal indifference enables endless re-litigation of foundational determinations.

The symptom is the mifepristone litigation. The disease is a misalignment between the finality required for pharmaceutical regulation and the perpetual reviewability granted by current doctrine.

Calibration One: Codify Heightened Standing Requirements for Pharmaceutical Challenges

Congress should amend the Administrative Procedure Act to require plaintiffs challenging premarket drug approvals to demonstrate direct, non-speculative injury traceable to their own interaction with the drug or its regulatory status. Specifically, insert a new subsection into 5 U.S.C. § 702 stipulating that standing to challenge an FDA drug approval under 21 U.S.C. § 355 requires either (1) direct economic harm from market competition, or (2) documented personal physical harm from the drug itself.

Authority: Congress, via amendment to the APA.

Structural Change: This narrows the universe of potential challengers to those with concrete, particularized injuries—the core Article III standard—while excluding ideological objections dressed as conscience-based harms. It does not eliminate judicial review; it ensures that review is sought by parties with actual regulatory stakes, not speculative grievances. The machinery shifts from open-access litigation to gatekept standing, consistent with constitutional requirements but legislatively clarified.

Calibration Two: Establish Mandatory Venue Consolidation for Nationwide Drug Approval Challenges

Congress or the Judicial Conference of the United States should create a mandatory multidistrict litigation pathway for any lawsuit challenging an FDA drug approval that seeks injunctive relief with nationwide effect. Under this framework, any such case filed in federal district court would be automatically transferred to a specialized panel (similar to the JPML process) for coordination and assignment to a single district court.

Authority: Congress (via statute) or the Judicial Conference (via rule amendment under the Rules Enabling Act, 28 U.S.C. § 2073).

Structural Change: This prevents forum shopping and conflicting injunctions. Rather than allowing plaintiffs to jurisdiction-shop for favorable judges in Texas or elsewhere, all challenges to a given drug approval are heard by a single court, ensuring consistency and preventing the regulatory chaos that arises when district courts issue contradictory nationwide orders. The system moves from decentralized, fragmented review to centralized adjudication—preserving access to courts while restoring order to pharmaceutical regulation.

Calibration Three: Implement Temporal Finality for Drug Approvals Older Than Ten Years

The FDA should adopt, via rulemaking under 21 U.S.C. § 371(a), a regulatory safe harbor providing that any drug approval in effect for more than ten years without suspension or withdrawal is presumptively final and unreviewable under the APA except in cases involving newly discovered safety data or fraud. Challenges based solely on disagreement with the original approval standard would be time-barred.

Authority: FDA, via notice-and-comment rulemaking.

Structural Change: This introduces temporal finality into pharmaceutical law. Long-settled approvals—particularly those supported by decades of post-market surveillance—are insulated from re-litigation based on retrospective disagreements. The change mirrors statutes of repose in other areas of law, balancing the need for accountability with the necessity of regulatory stability. The mechanism shifts from infinite reviewability to bounded review, with a clear temporal checkpoint.

Assessment: The Path Forward

Of the three Calibrations, Calibration Two—mandatory venue consolidation—is the most achievable in the near term. It does not require resolution of contentious standing debates or FDA rulemaking; it can be accomplished through procedural reform by the Judicial Conference or a narrow statutory fix. It also has bipartisan appeal: both regulatory proponents and opponents benefit from clarity and consistency in how challenges are adjudicated.

Calibration One is constitutionally sound but politically fraught, requiring Congress to legislate on standing in a polarized environment. Calibration Three faces resistance from both industry (wary of any limits on APA review) and advocacy groups (opposed to any insulation of agency decisions).

The minimum repair needed to prevent cascade failure is venue consolidation. Without it, every FDA approval—not just mifepristone—remains vulnerable to strategic forum shopping and contradictory injunctions. The system can survive imperfect standing doctrine and long approval timelines, but it cannot survive a regime in which a single district judge in a self-selected forum can override decades of regulatory science with nationwide effect. That is the core mechanism failure. Fixing it is the prerequisite for all other repairs.